(Press-News.org) This press release is available in French.
Researchers from the Guy Rouleau Laboratory affiliated with the CHUM Research Centre and the CHU–Sainte-Justine Research Centre have discovered the genetic cause of a rare disease reported only in patients originating from Newfoundland: hereditary spastic ataxia (HSA).
This condition is characterized by lower-limb spasticity (or stiffness) and ataxia (lack of coordination), the latter leading to speech and swallowing problems, and eye movement abnormalities. The disease is not deadly, but people start developing gait problems between 10 to 20 years of age, walk with a cane in their 30s, and in the most severe cases, are wheel-chair bound in their 50s. It has been shown that HSA is transmitted from the affected parent to the child in a dominant fashion, which means there is a 50% chance of the child having the mutation.
History of a discovery: collaboration between the University of Montreal and Memorial University
Researchers and clinicians from Memorial University (St. John's, Newfoundland) contacted Dr. Rouleau, who is also a professor of medicine at the University of Montreal, over a decade ago to investigate the genetics behind this disorder occurring in three large Newfoundland families. Dr. Inge Meijer, a former doctoral candidate in the Rouleau Laboratory, discovered that these families were ancestrally related, and in 2002, identified the locus (DNA region) containing the mutation causing HSA.
A few years later, Cynthia Bourassa, lead author of the study, took over Meijer's project. "I reexamined some unresolved details using newer and more advanced methods," explains Bourassa, who is a master's student in the Faculty of Medicine at the University of Montreal. She then teamed up with Dr. Nancy Merner, who after obtaining her Ph.D. at Memorial University moved to Montreal to further her career in genetic research. "It is an honour to be a part of this study and impact the lives of my fellow Newfoundlanders. I knew coming into the Rouleau Laboratory that the genetic factors of the HAS families had not yet been identified. In fact, I asked about them on my first day of work, shortly after which I teamed up with Cynthia and we found the gene!"
Scientific explanation:
The gene harbouring the mutation is VAMP1, encoding the synaptobrevin protein. "Not only was the mutation present in all patients and absent from all population controls, but also, synaptobrevin is a key player in neurotransmitter release, which made sense at the functional level as well," says Bourassa. In fact, the authors believe that this mutation in the VAMP1 gene may affect neurotransmission in areas of the nervous system where the synaptobrevin protein is located, causing the unique symptoms of HSA. In other words, there are not enough messengers released, so nerves cannot function optimally.
"The discovery will benefit the families affected with this extremely debilitating disorder," says Dr. Rouleau. "A genetic diagnostic test can be developed, and genetic counseling can be provided to family members who are at risk of developing the disease or having children with the condition."
Identification of the VAMP1 mutation was made in the Guy Rouleau Laboratory in collaboration with investigators from Newfoundland, Nova Scotia, and Ontario. Funding was provided by the Canadian Institutes for Health Research, the Canada Research Chair, and the Jeanne-et-J.-Louis-Levesque Chair for the Genetics of Brain Diseases.
###
About the study:
"VAMP1 Mutation Causes Dominant Hereditary Spastic Ataxia in Newfoundland Families." Authors: Cynthia V. Bourassa, Inge A. Meijer, Nancy D. Merner, Kanwal K. Grewal, Mark G. Stefanelli, Kathleen Hodgkinson, Elizabeth J. Ives, William Pryse-Phillips, Mandar Jog, Kym Boycott, David A. Grimes, Sharan Goobie, Richard Leckey, Patrick A. Dion, Guy A. Rouleau.
The American Journal of Human Genetics (2012), doi: 10.1016/j.ajhg.2012.07.018
The University of Montreal is known officially as Université de Montréal.
The CHU–Sainte-Justine and CHUM are acronyms for the Centre hospitalier universitaire Sainte-Justine and the Centre hospitalier de l'Université de Montréal, respectively.
About the researchers:
Dr. Guy A. Rouleau, M.D., Ph. D., Professor, Faculty of Medicine, Université de Montréal, Director of the CHU–Sainte-Justine Research Centre, Investigator at the Centre hospitalier de l'Université de Montréal (CHUM).
Cynthia Bourassa, B.Sc., Master's Student, Faculty of Medicine, Université de Montréal
Dr. Nancy Merner, Ph.D., Post-Doctoral Fellow, Faculty of Medicine, Université de Montréal
Dr. Inge Meijer, M.D., Ph.D., Neuropediatric Resident, Faculty of Medicine, Université de Montréal
Stage I, non-small cell lung cancer (NSCLC) patients who received radiation therapy have an increased median survival of 21 months compared to 16 months, and the percentage of patients who receive no treatment declined from 20 percent to 16 percent, respectively, when comparing the two eras evaluated, 1999-2003 and 2004-2008, according to detailed analysis of the SEER-17 (Surveillance Epidemiology and End Results, National Cancer Institute) national database presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the ...
Stage III non-small cell lung cancer (NSCLC) patients treated with surgery and/or radiation therapy have a significantly reduced risk of developing brain metastases if they also receive prophylactic cranial irradiation (PCI); however, this study did not show an improvement in overall survival with PCI, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the ...
TORONTO, Sept. 6, 2012 – Imagine that the players on your favourite football team were smaller than their opponents, and had to play without helmets or pads. Left defenseless, they would become easy prey for other teams. Similarly, changes in Canadian lake water chemistry have left small water organisms vulnerable to their predators, which may pose a serious environmental threat, according to a new study.
"At low calcium levels the organisms grow slower and cannot build their armour," says study lead author Howard Riessen, professor of biology, SUNY College at Buffalo. ...
Treatment with pemetrexed, carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab (Pem+Cb+B) is no better than standard therapy with paclitaxel, carboplatin and bevacizumab followed by bevacizumab (Pac+Cb+B) in patients with advanced non-squamous non-small cell lung cancer (NS-NSCLC), according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association ...
SAN ANTONIO (Sept. 6, 2012) — RSV, a virus that causes respiratory infections in infants and young children, selectively kills cancer cells while leaving healthy cells alone, researchers from the School of Medicine at The University of Texas Health Science Center San Antonio said.
Santanu Bose, Ph.D., of the School of Medicine, is the inventor on a pending U.S. patent of RSV as an oncolytic therapy. This represents a new use for the virus. Bandana Chatterjee, Ph.D., of the School of Medicine and the South Texas Veterans Health Care System, is the co-inventor. Oncolytic ...
Every ten years or so, someone will make the observation that there is a lack of political diversity among psychological scientists and a discussion about what ought to be done ensues. The notion that the field discriminates against and is skewed toward a liberal political perspective is worthy of concern; scholars, both within and outside the field, have offered various solutions to this diversity problem.
As psychological scientists Yoel Inbar and Joris Lammers point out, however, we have few of the relevant facts necessary to understand and address the issue.
In ...
Pick your poison: sun exposure that leads to skin cancer or low physical activity that leads to obesity? In fact, a University of Colorado Cancer Center study published this week in the journal Preventing Chronic Disease shows that parents' concern about skin cancer doesn't make them keep their kids indoors.
"Actually, our hypothesis was the opposite – that if parents were concerned about skin cancer they wouldn't let their children go out as much," says Alexander Tran, summer fellow working with Lori Crane, PhD, CU Cancer Center investigator and chair of the Department ...
GAINESVILLE, Fla. — University of Florida scientists publishing the first study on butterflies and moths of Guantanamo Bay Naval Station have discovered vast biodiversity in an area previously unknown to researchers.
Appearing in the Bulletin of the Allyn Museum Sept. 5, the study creates a baseline for understanding how different plant and animal species have spread throughout the Caribbean.
"Biodiversity studies are extremely important because they give us clues about where things were and how they evolved over time so we can better understand what may happen in ...
CAMBRIDGE, MA -- Competition is a strong driving force of evolution for organisms of all sizes: Those individuals best equipped to obtain resources adapt and reproduce, while others may fall by the wayside. Many organisms — mammals, birds and insects, for instance — also form cooperative social structures that allow resources to be defended and shared within a population.
But surprisingly, even microbes, which are thought to thrive only when able to win the battle for resources against those nearest to them, have a somewhat sophisticated social structure that relies on ...
A study of survival data for Stage III, non-small cell lung cancer (NSCLC) patients at the University of Maryland's Greenebaum Cancer Center in Baltimore indicates that marital status and race can significantly impact patient survival rates, according to research presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), the International Association for the Study of Lung Cancer (IASLC), and The University of Chicago.
This ...
